Pure Global
NCT04747639

Glycemic Response to Two Doses of Low Sugar Apple Juice

Double-blind, Randomized, Controlled, Four Treatment Four Period Cross-over Trial on Glycemic Response, Excretion of Gluconate and Tolerability of Two Doses of Low Sugar Apple Juice
Clinical Research Center Kiel GmbH·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Prediabetes
Drug/Device/Intervention
500 ml glucose-depleted apple juice
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Clinical Research Center Kiel GmbH
Location
Kiel, Germany
Timeline & enrollment
Phase
N/A
Start date
Oct 28, 2015
End date
Feb 01, 2021
Enrollment
32 participants
Primary outcome

iAUC glucose 500,iAUC insulin 500,iAUC glucose 250,iAUC insulin 250

Summary

Single center, double-blind, randomized controlled cross-over trial with four treatments and
 four time points.
 
 The study has three primary objectives. The first primary objective is to confirm the
 reduction of postprandial glycemic and insulinemic response after consumption of 500 ml
 glucose-free apple juice compared to 500 ml untreated apple juice as could be shown in a
 previous study

ICD-10 classifications
Diabetes mellitusDiabetes mellitus in pregnancy: Pre-existing diabetes mellitus, unspecifiedOther specified diabetes mellitusDiabetes mellitus in pregnancy: Pre-existing diabetes mellitus, non-insulin-dependentDiabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04747639
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04747639 through Pure Global AI's free database. This phase not specified trial is sponsored by Clinical Research Center Kiel GmbH and is currently Completed. The study focuses on Prediabetes. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.